Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine Use on Healthcare Workers Exposed to COVID-19 - A Pandemic Hospital Experience

Polat et al., Medical Journal of Bakirkoy, 16:3, 280-6, doi:10.5222/BMJ.2020.50469
Sep 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Case 57% Improvement Relative Risk HCQ for COVID-19  Polat et al.  Prophylaxis Is post-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 208 patients in Turkey Fewer cases with HCQ (p=0.026) Polat et al., Medical J. Bakirkoy, 280-6, Sep 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments.
Small prophylaxis study of 208 healthcare workers in Turkey, 138 with high risk exposure received HCQ, while 70 with low and medium risk exposure did not. COVID-19 cases were lower in the treatment group, relative risk RR 0.43, p = 0.026. Since the control group had lower risk, the actual benefit may be larger.
risk of case, 57.0% lower, RR 0.43, p = 0.03, treatment 12 of 138 (8.7%), control 14 of 70 (20.0%), NNT 8.8.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Polat et al., 30 Sep 2020, prospective, Turkey, peer-reviewed, 3 authors.
This PaperHCQAll
Hydroxychloroquine Use on Healthcare Workers Exposed to COVID-19 -A Pandemic Hospital Experience
Özlem Polat, Ramazan Korkusuz, Murathan Berber
Medical Journal of Bakırkoy, doi:10.5222/bmj.2020.50469
Objective: As healthcare professionals play a role in combating the COVID-19 outbreak, the risk of disease exposure and illness increases. In our study, we aimed to measure the effectiveness of post-contact use in order to protect the healthcare professionals who work very intensively during the outbreak. Method: A total of 208 healthcare workers who applied to Employee Health Unit section between the dates 25 March-25 April 2020 with a history of contact with COVID-19 patients were included in the study. Employees were evaluated in low, moderate and high risk groups according to the Contact Risk Algorithm included in the Evaluation of Healthcare Workers Guidelines with COVID-19 theme. Three-day hydroxychloroquine treatment was initiated to 138 healthcare professionals who were considered as high risk. The treatment regimen was arranged as 2x400 mg on the first day and 2x200 mg on the 2 nd and 3 rd days. The COVID-19 positivity rates were analyzed according to the contact risk groups Results: There was a statistically significant difference between occupational groups according to contact risk groups (p<0.01); the rate of contact risk of nurses in the middle, and the doctors in the high risk groups was found to be significantly higher. When the COVID-19 positivity rates were analyzed according to the contact risk groups, the COVID-19 positivity rates were 9.4% in the high-, 16.3% in the moderate and 14.3% in the low-risk groups. The contact was found to be related to the COVID-19 test, and the positivity rate from contact with the patient was found to be significantly high (p<0.01). Conclusion: Recommendations about hydroxychloroquine for postexposure prophylaxis vary. Hydroxychloroquine can be a possible effective agent in postexposure prophylaxis. We think that conducting similar studies on larger samples can provide significant benefits to individuals and public health.
Backer, Klinkenberg, Wallinga, Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28, Euro Surveill, doi:10.2807/1560
Han, Lin, You, Coronavirus 2019-nCoV: A brief perspective from the front line, J Infect, doi:10.1016/j.jinf.2020.02.010
Hoffmann, Treatment
Lother, Abassi, Agostinis, Bangdiwala, Cheng et al., Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomizedcontrolled trial, Can J Anaesth, doi:10.1007/s12630-020-01684-7
Lu, Chen, Lee, Chang, Potential therapeutic agents against COVID-19: What we know so far, J Chin Med Assoc, doi:10.1097/JCMA.0000000000000318
Lu, Danni, Xinlan, Yujuan, You et al., Correlation between hand hygiene compliance and nosocomial infection in medical staff, Chinese Journal of Disinfection
Nguyen, Drew, Joshi, Risk of COVID-19 among frontline healthcare workers and the general community: a prospective cohort study, doi:10.1101/2020.04.29.20084111
Pagliano, Piazza, Caro, Ascione, Filipelli, Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to Healthcare Workers Exposed to Coronavirus Disease 2019?, Clin Infect Dis, doi:10.1093/cid/ciaa320
Ran, Chen, Wang, Risk factors of healthcare workers with corona virus disease 2019: a retrospective cohort study in a designated hospital of Wuhan in China, Clin Infect Dis, doi:10.1093/cid/ciaa287
Rathi, Ish, Kalantri, Kalantri, Hydroxychloroquine prophylaxis for Covid-19 contacts in India, Lancet Infect Dis, doi:10.1016/S1473-3099(20
Schrezenmeie, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol, doi:10.1038/s41584-020-0372-x
Schwartz, King, Protecting Healthcare Workers During the Coronavirus Disease 2019 (COVID-19) Outbreak: Lessons From Taiwan's Severe Acute Respiratory Syndrome Response, Clin Infect Dis, doi:10.1093/cid/ciaa255
Tang, Bidon, Jaimes, Coronavirus membrane fusion mechanism offers a potential target for antiviral development, Antiviral Res, doi:10.1016/j.antiviral.2020.104792
Wan, Shang, Graham, Baric, Li, Receptor recognition by novelcoronavirus from Wuhan: An analysis based on decade-long structural studies of SARS, J Virol, doi:10.1128/JVI.00127-20
Wang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
{ 'indexed': {'date-parts': [[2022, 3, 29]], 'date-time': '2022-03-29T01:21:28Z', 'timestamp': 1648516888262}, 'reference-count': 0, 'publisher': 'Galenos Yayinevi', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020]]}, 'DOI': '10.5222/bmj.2020.50469', 'type': 'journal-article', 'created': {'date-parts': [[2020, 10, 5]], 'date-time': '2020-10-05T10:12:38Z', 'timestamp': 1601892758000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Hydroxychloroquine Use on Healthcare Workers Exposed to COVID-19 -A Pandemic Hospital Experience', 'prefix': '10.4274', 'author': [ {'given': 'Özlem', 'family': 'Polat', 'sequence': 'first', 'affiliation': []}, {'given': 'Ramazan', 'family': 'Korkusuz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Murathan', 'family': 'Berber', 'sequence': 'additional', 'affiliation': []}], 'member': '2811', 'published-online': {'date-parts': [[2020]]}, 'container-title': 'Medical Journal of Bakırkoy', 'original-title': [], 'deposited': { 'date-parts': [[2021, 6, 18]], 'date-time': '2021-06-18T10:33:21Z', 'timestamp': 1624012401000}, 'score': 1, 'resource': {'primary': {'URL': ''}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020]]}, 'references-count': 0, 'URL': '', 'relation': {}, 'ISSN': ['1305-9319'], 'subject': ['General Medicine'], 'container-title-short': 'BMJ', 'published': {'date-parts': [[2020]]}}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop